Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed.
Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor …

COVID-19 is a clinical syndrome ranging from mild symptoms to severe pneumonia that
often leads to respiratory failure, need for mechanical ventilation, and death. Most of the lung …

The COVID-19 pandemic is a global public health crisis, with considerable mortality and
morbidity exerting pressure on health-care resources, including critical care. An excessive …

GM-CSF promotes myelopoiesis and inflammation, and GM-CSF blockade is being
evaluated as a treatment for COVID-19-associated hyperinflammation. Alveolar GM-CSF is …

Background In patients with COVID-19, granulocyte-macrophage colony stimulating factor
(GM-CSF) might be a mediator of the hyperactive inflammatory response associated with …

While it is now widely accepted that host inflammatory responses contribute to lung injury,
the pathways that drive severity and distinguish coronavirus disease 2019 (COVID-19) from …

The recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic …

COVID-19 has claimed millions of lives during the last 3 years since initial cases were
reported in Wuhan, China, in 2019. Patients with COVID-19 suffer from severe pneumonia …

An emerging, rapidly spreading coronavirus SARS-CoV-2 is causing a devastating
pandemic. As we have not developed curative medicine and effective vaccine, the end of …

cov-Abstract Emerging studies from SARS-CoV-2-infected patients indicate a preponderant
role of monocytes/macrophages in the pathogenesis of this viral infection, in a similar way to …